However, T2DM-BMSC-EXOs treatment has been demonstrated to significantly decrease activated microglia, M1 macrophage, and inflammatory factors MMP-9 and MCP-1 expression in the ischemic brain in T2DM stroke rats (35). This evidence concerns the gene MMP9 and type 2 diabetes mellitus.